
Servier and MiNA Therapeutics sign €220m deal
Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...

Cellink AB acquires Ginolis Oy for €70m
Under the agreement, Cellink AB is set to acquire all shares for a purchase price on cash- and debt-free basis of €70m. Forty per cent of the...

Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

J&J starts European COVID-19 vaccine roll-out
According to the EMA, the very rare cases of cerebral venous thrombosis, which were observerd after vaccination with J&J’s COVID-19 jab, didn't...

InteRNA Technologies secures €18.5m in Series B financing
Waterman Ventures and current shareholders Aglaia Oncology Funds and OostNL participated in the funding. The Utrecht-based...

Targeting SARS-CoV-2 differently
Using X-ray crystallography, Sebastian Günther and colleagues screened more than 5,000 drug compounds, identified seven compounds that bind to Mpro,...